Single agent lenalidomide in newly diagnosed multiple myeloma: A retrospective analysis

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 1015-1019

  Baz, Rachid ^a   Patel, Mehul ^b   Finley Oliver, Elizabeth ^a   Lebovic, Daniel ^a   Hussein, Mohamad A ^c   Miller, Kena C ^b   Wood, Margaret ^b   Sher, Taimur ^b   Lee, Kelvin ^b   Chanan Khan, Asher A ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

Immune modulation; Lenalidomide; Multiple myeloma

Indexed keywords

LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; RETROSPECTIVE STUDIES; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77953513419     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003721342     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132.
3. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.
4. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
5. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.
6. Chanan-Khan A, Miller KC, Musial L, et al. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma 2009;50:1096-1101.
7. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
8. Chanan-Khan AA, Cheson BD.Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-1552.
9. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111: 5291-5297.
10. Schafer PH, Gandhi AK, Zhang L-H, et al. Opposing effects of dexamethasone on lenalidomide activity in multiple myeloma: additive/synergistic effects on anti-proliferative activity on myeloma cells and antagonistic effects on immune function. Blood 2008;112(Suppl. 1):953 (Abstract 2761).
11. Miguel JFS, Dimopoulos M, Weber D, et al. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/ dexamethasone (MM009/010 sub-analysis). Blood 2007;110(Suppl. 1):796a (Abstract 2712).
12. Rajkumar S, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2007; 110(Suppl. 1):31a (Abstract 74).
13. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
14. Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:4851-4852; author reply 4852-4853.
15. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(Suppl. 1): I107-I113.
16. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
17. Gandhi AK, Rogovitz A, Lopez-Girona A, et al. Stimulation of T cells by lenalidomide involves putative lenalidomide binding proteins CD3-epsilon-associated protein and GDP-mannose pyrophosphorylase a. Blood 2008;112(Suppl. 1):903 (Abstract 2606).
18. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-3464.
19. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17: 775-779.
20. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21: 16-19.
21. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518-3525.
22. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-1184.
23. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overallresponse rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-1109.